OIM
INKT icon

Oracle Investment Management’s MiNK Therapeutics INKT Stock Holding History

Oracle Investment Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,690
Closed -$39.5K – 28
2023
Q4 		$39.5K Hold
3,690
– – 0.02% 26
2023
Q3 		$40.6K Sell
3,690
-1,356
-27% -$22.1K 0.01% 23
2023
Q2 		$106K Buy
+5,046
New +$101K 0.08% 29

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oracle Investment Management's INKT Position: Q1 2024 in Review

Oracle Investment Management sold out of MiNK Therapeutics (INKT) in Q1 2024, closing a stake of 3,690 shares — an estimated $39.5K sold.

Oracle Investment Management first reported a position in INKT in Q2 2023 and held it in 3 quarters. The position peaked at $106K in Q2 2023. 33 funds tracked by Wall St. Rank hold INKT as of Q1 2024.

  • Oracle Investment Management reported no remaining MiNK Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Oracle Investment Management sold 3,690 MiNK Therapeutics shares in Q1 2024, an estimated $39.5K.
  • Oracle Investment Management first reported a position in MiNK Therapeutics in Q2 2023 and held it in 3 quarters.
  • Oracle Investment Management's MiNK Therapeutics position peaked at $106K in Q2 2023.
  • 33 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2024.

Based on Oracle Investment Management's 13F filing for Q1 2024, filed 15 May 2024.